36 | ruxolitinibIBA
11/2023
-
06/2012 |
15 | Janus Kinase InhibitorsIBA
12/2023
-
01/2013 |
12 | 11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA
10/2023
-
01/2018 |
11 | Hydroxyurea (Hydrea)FDA LinkGeneric
11/2023
-
03/2016 |
9 | CytokinesIBA
01/2024
-
08/2011 |
7 | InterferonsIBA
01/2024
-
11/2010 |
7 | fedratinibIBA
09/2023
-
01/2020 |
7 | Phosphotransferases (Kinase)IBA
10/2021
-
01/2015 |
6 | Janus KinasesIBA
10/2023
-
01/2013 |
6 | Proteins (Proteins, Gene)FDA Link
12/2022
-
08/2011 |
5 | Biomarkers (Surrogate Marker)IBA
11/2023
-
01/2018 |
4 | Janus Kinase 2IBA
01/2022
-
11/2010 |
3 | Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2023
-
03/2016 |
3 | Hemoglobins (Hemoglobin)IBA
11/2023
-
01/2018 |
3 | imetelstatIBA
07/2022
-
10/2021 |
3 | anagrelide (Agrylin)FDA LinkGeneric
01/2022
-
06/2015 |
3 | RG7388IBA
01/2022
-
01/2019 |
3 | AnticoagulantsIBA
10/2021
-
01/2020 |
3 | CollagenIBA
01/2021
-
01/2016 |
3 | Histone Deacetylase InhibitorsIBA
01/2017
-
07/2012 |
3 | PanobinostatIBA
01/2017
-
07/2012 |
2 | Interferon-alpha (Interferon Alfa)IBA
11/2023
-
06/2010 |
2 | Syntex adjuvant formulationIBA
10/2023
-
01/2022 |
2 | micaIBA
12/2022
-
01/2022 |
2 | AntibodiesIBA
12/2022
-
10/2020 |
2 | Immunomodulating AgentsIBA
12/2022
-
11/2010 |
2 | Telomerase (Telomerase Reverse Transcriptase)IBA
07/2022
-
10/2021 |
2 | peginterferon alfa-2a (Pegasys)FDA Link
01/2022
-
10/2019 |
2 | venetoclaxIBA
04/2021
-
11/2020 |
2 | lestaurtinibIBA
01/2019
-
01/2015 |
2 | Janus Kinase 1IBA
01/2018
-
03/2016 |
2 | Reticulin (Reticular Fiber)IBA
09/2017
-
01/2016 |
2 | Antidepressive Agents (Antidepressants)IBA
01/2017
-
01/2017 |
2 | Thrombopoietin (c-mpl Ligand)IBA
01/2016
-
01/2013 |
2 | Transforming Growth Factors (Transforming Growth Factor)IBA
01/2016
-
02/2014 |
2 | ErythropoietinFDA Link
01/2013
-
04/2012 |
2 | ChromatinIBA
08/2011
-
11/2010 |
1 | Activin Receptors (Activin Receptor)IBA
10/2023 |
1 | activin AIBA
10/2023 |
1 | HepcidinsIBA
10/2023 |
1 | Serum Amyloid P-ComponentIBA
10/2023 |
1 | N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA
04/2023 |
1 | Interleukin-15 (Interleukin 15)IBA
12/2022 |
1 | LigandsIBA
12/2022 |
1 | AntigensIBA
12/2022 |
1 | Testosterone CongenersIBA
12/2022 |
1 | FluoroquinolonesIBA
12/2022 |
1 | Interleukin-6 (Interleukin 6)IBA
12/2022 |
1 | Anti-Inflammatory Agents (Anti-Inflammatories)IBA
12/2022 |
1 | navtemadlin; 2- ((3R,5R,6S)- 5- (3- chlorophenyl)- 6- (4- chlorophenyl)- 1- ((S)- 1- (isopropylsulfonyl)- 3- methylbutan- 2- yl)- 3- methyl- 2- oxopiperidin- 3- yl)acetic acidIBA
11/2022 |
1 | Immunoglobulin G (IgG)IBA
06/2022 |
1 | blinatumomabIBA
06/2022 |
1 | Immunoglobulins (Immunoglobulin)IBA
06/2022 |
1 | Intravenous Immunoglobulins (IVIG)FDA Link
06/2022 |
1 | Drug CombinationsIBA
01/2022 |
1 | dimemorfan (AT 17)IBA
01/2022 |
1 | Peptides (Polypeptides)IBA
01/2022 |
1 | Interleukin-1 Receptor-Associated KinasesIBA
01/2022 |